734 related articles for article (PubMed ID: 17054774)
1. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
2. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
[TBL] [Abstract][Full Text] [Related]
3. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
4. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
6. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.
Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y
Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422
[TBL] [Abstract][Full Text] [Related]
7. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene.
Casey G; Lo-Hsueh M; Lopez ME; Vogelstein B; Stanbridge EJ
Oncogene; 1991 Oct; 6(10):1791-7. PubMed ID: 1923504
[TBL] [Abstract][Full Text] [Related]
8. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
Reiss M; Brash DE; Muñoz-Antonia T; Simon JA; Ziegler A; Vellucci VF; Zhou ZL
Oncol Res; 1992; 4(8-9):349-57. PubMed ID: 1486218
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
10. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y; Bodmer WF
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
[TBL] [Abstract][Full Text] [Related]
11. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
12. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
13. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
14. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas.
Huang Y; Meltzer SJ; Yin J; Tong Y; Chang EH; Srivastava S; McDaniel T; Boynton RF; Zou ZQ
Cancer Res; 1993 Apr; 53(8):1889-94. PubMed ID: 8467510
[TBL] [Abstract][Full Text] [Related]
15. Distinct promoter usage of mdm2 gene in human breast cancer.
Okumura N; Saji S; Eguchi H; Nakashima S; Saji S; Hayashi S
Oncol Rep; 2002; 9(3):557-63. PubMed ID: 11956627
[TBL] [Abstract][Full Text] [Related]
16. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma.
van Slooten HJ; van De Vijver MJ; Borresen AL; Eyfjörd JE; Valgardsdóttir R; Scherneck S; Nesland JM; Devilee P; Cornelisse CJ; van Dierendonck JH
J Pathol; 1999 Dec; 189(4):504-13. PubMed ID: 10629550
[TBL] [Abstract][Full Text] [Related]
17. Loss of alternately spliced messenger RNA of the luteinizing hormone receptor and stability of the follicle-stimulating hormone receptor messenger RNA in granulosa cell tumors of the human ovary.
Reinholz MM; Zschunke MA; Roche PC
Gynecol Oncol; 2000 Nov; 79(2):264-71. PubMed ID: 11063655
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of p53 alterations throughout breast cancer progression.
Davidoff AM; Kerns BJ; Iglehart JD; Marks JR
Cancer Res; 1991 May; 51(10):2605-10. PubMed ID: 1850660
[TBL] [Abstract][Full Text] [Related]
19. Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors.
Vitale L; Frabetti F; Huntsman SA; Canaider S; Casadei R; Lenzi L; Facchin F; Carinci P; Zannotti M; Coppola D; Strippoli P
BMC Cancer; 2007 Apr; 7():66. PubMed ID: 17442112
[TBL] [Abstract][Full Text] [Related]
20. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
